Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML

Blood Adv. 2023 Mar 14;7(5):681-686. doi: 10.1182/bloodadvances.2022008991.

Affiliations

¹ Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
² Division of Clinical Laboratory, Okayama University Hospital, Okayama, Japan.
³ Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aniline Compounds / adverse effects
Humans
Leukemia, Myeloid, Acute* / chemically induced
Neoplasm Recurrence, Local*
Pyrazines / adverse effects

Substances

gilteritinib
Aniline Compounds
Pyrazines